Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05715281 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoints removed 3 → 1 primary endpoints
See other at-risk trials from National Cancer Institute (NCI)

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 4 more changesShow less
    • Results posted: Oct 14, 2026
    • Eligibility criteria expanded, about 51 words
    • Secondary endpoints: 2 to 3
    • Study description expanded, about 4 words
  2. Enrollment target: estimated 15 to confirmed 12
    • Primary completion date changed from estimate of Oct 15, 2026 to Oct 6, 2025
    • Study completion date: Oct 15, 2026 to Nov 21, 2026
    v34
  3. 2 versions Re-verified since Sep 2, 2025, no change to tracked fieldsv32-v33
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v31
  5. Re-verified, no change to tracked fieldsv30
Show 28 earlier versionsHide 28 earlier versions
  1. Interventions: Atezolizumab (Biological), Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography… to Atezolizumab (Biological), Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure)…v29
  2. Site details revised at 1 of 3 sitesv28
  3. Site details revised at 1 of 3 sitesv27
  4. Re-verified, no change to tracked fieldsv26
  5. Eligibility criteria shortened, about 17 wordsv25
  6. Study sites: 2 to 3v24
  7. Site details revised at 1 of 2 sitesv23
  8. Re-verified, no change to tracked fieldsv22
  9. Eligibility criteria revised
    • Secondary endpoints revised (2)
    • Study description shortened, about 37 words
    v21
  10. Eligibility criteria expanded, about 9 wordsv20
  11. Re-verified, no change to tracked fieldsv19
  12. Site details revised at 2 of 2 sitesv18
  13. Site details revised at 1 of 2 sitesv17
  14. Re-verified, no change to tracked fieldsv16
  15. Study description expanded, about 7 wordsv15
  16. 2 versions Re-verified since Feb 23, 2024, no change to tracked fieldsv13-v14
  17. Study sites: 3 to 2
    • Study description expanded, about 11 words
    v12
  18. Start date changed from estimate of Jan 6, 2024 to Sep 26, 2023v11
  19. Re-verified, no change to tracked fieldsv10
  20. Start date: Oct 8, 2023 to Jan 6, 2024v9
  21. Re-verified, no change to tracked fieldsv8
  22. Study sites: 1 to 3v7
  23. Start date: Jun 26, 2023 to Oct 8, 2023v6
  24. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of May 10, 2023 to Jun 26, 2023
    • Study description expanded, about 56 words
    • Eligibility criteria shortened, about 4 words
  25. 2 versions Re-verified since Apr 22, 2023, no change to tracked fieldsv3-v4
  26. Primary and study completion dates: Apr 1, 2025 to Oct 15, 2026
    • Start date: Feb 10, 2023 to May 10, 2023
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well atezolizumab works in combination with tiragolumab in treating patients with rare solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced stage). Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The study biopsy takes small pieces of cancer tissue from a tumor. The purpose of these biopsies is to compare the body's immune response against the tumor before and after treatment with the study drugs. Blood samples will also be collected for the study. The researchers will use the samples to learn more about how atezolizumab and tiragolumab work and which patients in the future might be most likely to respond to atezolizumab and tiragolumab. Using atezolizumab in combination with tiragolumab may help to shrink tumors in patients diagnosed with advanced stage rare solid-tumor cancers.
Trial Details
NCT Number NCT05715281
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov